Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A R Tan

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Seminars in Oncology|August 11, 2001
Adjuvant chemotherapy for breast cancer: an updateA R Tan, S M Swain
Seminars in Oncology|November 14, 2001
Novel agents: clinical trial designA R Tan, S M Swain
Osteoarthritis and Cartilage|September 21, 2010
Response of engineered cartilage to mechanical insult depends on construct maturityA R Tan, E Y Dong, G A Ateshian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2007
Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatmentA R Tan, S M Steinberg, A L Parr, et al.
Osteoarthritis and Cartilage|December 3, 2014
Passage-dependent relationship between mesenchymal stem cell mobilization and chondrogenic potentialA R Tan, E Alegre-Aguarón, G D O'Connell, et al.
British Journal of Cancer|May 8, 2014
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignanciesA R Tan, A Dowlati, M N Stein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 studyS Adams, P Schmid, H S Rugo, et al.
Breast Cancer Research and Treatment|December 28, 2014
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II studyA R Tan, H Johannes, P Rastogi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 studyS Adams, S Loi, D Toppmeyer, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Seminars in Oncology|August 11, 2001
Adjuvant chemotherapy for breast cancer: an updateA R Tan, S M Swain
Seminars in Oncology|November 14, 2001
Novel agents: clinical trial designA R Tan, S M Swain
Osteoarthritis and Cartilage|September 21, 2010
Response of engineered cartilage to mechanical insult depends on construct maturityA R Tan, E Y Dong, G A Ateshian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2007
Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatmentA R Tan, S M Steinberg, A L Parr, et al.
Osteoarthritis and Cartilage|December 3, 2014
Passage-dependent relationship between mesenchymal stem cell mobilization and chondrogenic potentialA R Tan, E Alegre-Aguarón, G D O'Connell, et al.
British Journal of Cancer|May 8, 2014
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignanciesA R Tan, A Dowlati, M N Stein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 studyS Adams, P Schmid, H S Rugo, et al.
Breast Cancer Research and Treatment|December 28, 2014
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II studyA R Tan, H Johannes, P Rastogi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 studyS Adams, S Loi, D Toppmeyer, et al.
Pageof 1